CClinicalTrials.gg
Status unknownNCT03280459iRARC-KSWUpdated Sep 12, 2017

Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction

An observational study in Urothelial Carcinoma, Cystectomy and Urinary Diversion, sponsored by Kantonsspital Winterthur KSW. Status unknown at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-12.

Sponsored by Kantonsspital Winterthur KSW · Observational

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

Continous evaluation of clinical and oncologic outcome of robot-assisted cystectomy with intracorporeal reconstruction of urinary diversion. Patient Data is entered in an anonymized registry for analyzation.

Read the detailed description

The registry includes patients after robot-assisted cystectomy, mainly as therapy for muscle invasive urothelial carcinoma. The urinary diversion will be completed intracorporeal either as ileal conduit or ileal neobladder. Outcome parameters include perioperative complications, oncologic data and oncologic follow-up data (tumor classification, recurrence, survival) as well as data on functional follow up (continence, quality of life).

02

Conditions studied

  • Urothelial Carcinoma
  • Cystectomy
  • Urinary Diversion
  • Complication of Surgical Procedure
  • Complication, Postoperative
  • Neobladder
  • Ileal Conduit
  • Robotic Surgical Procedures
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Onkologic patients that qualify for radical cystectomy according to institutional tumor-board decision or patients with functional indications after failure of all other therapy modalities and receive a cystectomy

Inclusion criteria

  • age 18 years
  • informed consent for operation and data use
  • Oncologic patients that qualify for radical cystectomy according to institutional tumor-board decision or patients with functional indications after failure of all other therapy modalities and receive a cystectomy

Exclusion criteria

Exclusion Criteria:

  • age \<18 years
  • declined informed consent / data use
  • pregnancy
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Ileal Conduit

    Patient with ileal conduit as reconstruction of urinary diversion after robot-assisted cystectomy

    Procedure: robot-assisted cystectomy

  • Neobladder

    Patient with neobladder, (orthotopic, continent ileal pouch) as reconstruction of urinary diversion after robot-assisted cystectomy

    Procedure: robot-assisted cystectomy

Interventions

  • Procedurerobot-assisted cystectomy

    Removal of urinary bladder in oncologic or functional setting using a assistance of a operation robotic for laparoscopy

05

What researchers measure

Primary outcomes

  1. postoperative complications

    deviations from normal postoperative course \["Clavien-Dindo" Grade\]

    Time frame: 1 year

Secondary outcomes

  1. Treatment of tumor recurrence

    Treatment of tumor recurrence (radiotherapy, chemotherapy, operation)

    Time frame: through study completion, an average of 5 years

  2. Quality of Life urology specific

    EORTC-BLM 30 (European Organisation for Research and Treatment of Cancer Questionaire for muscle invasive bladder cancer) questionaire for evaluation of quality of life for patients with muscle invasive bladder cancer

    Time frame: 1 year

  3. Quality of Life overall

    EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionaire) questionaire for evaluation of quality of life for oncologic patients

    Time frame: 1 year

  4. Operation Time

    duration of operation \[min\]

    Time frame: expected 4-8 hours

  5. Postoperative Death by any cause

    Death by any cause \[n/months\]

    Time frame: through study completion, an average of 5 years

  6. Pouch capacity

    interventional measurement of pouch capacity with pressure recording catheter \[ml\]

    Time frame: 1 year

  7. Type of tumor-recurrence

    Location of tumor recurrence (local, metastasis)

    Time frame: through study completion, an average of 5 years

  8. Blood loss

    blood loss during operation \[ml\]

    Time frame: expected 4-8 hours

  9. Time to recurrence

    time until recurrence of tumor \[months\]

    Time frame: through study completion, an average of 5 years

  10. Tumor specific death

    Time to tumor specific death \[months\]

    Time frame: through study completion, an average of 5 years

  11. Preoperative Tumor staging

    Preoperative Tumor staging according UICC TNM System (Union internationale contre le cancer Tumor Nodus Metastasis System)

    Time frame: 90 days

  12. Postoperative Tumor staging

    Postoperative Tumor staging according UICC TNM System (Union internationale contre le cancer Tumor Nodus Metastasis System)

    Time frame: 90 days

  13. Pouch-pressure

    interventional measurement of pouch-pressure \[cmH2O\]with pressure recording catheter

    Time frame: 1 year

  14. Postvoid residual urine

    Residual urin after voiding \[ml\]

    Time frame: 1 year

  15. Functional length of urethral sphincter

    interventional measurement of Functional length of urethral sphincter \[mm\] with pressure recording catheter

    Time frame: 1 year

  16. Functional pressure of urethral sphincter

    interventional measurement of functional pressure of urethral sphincter \[cmH2O\] with pressure recording catheter

    Time frame: 1 year

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: Undecided — depersonalized Data may be shared with other academic centers if data security and ethical considerations equal to swiss standards are followed

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03280459
Lead sponsor
Kantonsspital Winterthur KSW
Responsible party
Christoph Schregel (Assistenzarzt Urologie / resident Departement of Urology, Kantonsspital Winterthur KSW) — Principal investigator
First posted
Sep 12, 2017
Start date
Jan 1, 2015
Primary completion
Jun 1, 2023 (estimated)
Completion
Jun 1, 2023 (estimated)
Last update
Sep 12, 2017

Study contacts

Christoph Schregel, MD
Contact
christophschregel@gmx.de
Orlando Burkhardt, MD
Contact
+41792912821

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion